We Work for Health | Washington

10/17/2025

"President Trump is trying to expand that price control regime by instituting a Most Favored Nation policy, which would anchor U.S. drug prices to the artificially low prices that prevail in Italy and other European countries."

won't work in the U.S.: https://www.realclearhealth.com/articles/2025/10/09/americans_should_copy_italians_recipes_not_our_healthcare_system_1139780.html

10/15/2025

"In any normal market—whether it’s a retail outlet or a grocery store—prices are clearly displayed for consumers to see and make their purchasing decisions accordingly. But when it comes to pharmaceuticals, patients often have no idea what their prescription costs overall, what their share of the bill will be at the pharmacy counter, and what alternatives exist."

Patients sense they’re being taken advantage of — and they’re often correct. Direct-to-consumer sales enable Americans to cut out the middlemen.

10/13/2025

Bipartisan leaders are stepping up to stop $124B in Medicare overbilling. The Act puts patients and physicians back at the center of care — not corporate algorithms.
https://dcjournal.com/republicans-have-found-124-billion-in-medicare-fraud-now-what/

10/10/2025

"We urge policymakers to pursue approaches that abide by federal law and regulations that prohibit discrimination against people with disabilities. The United States must prioritize early access to innovations that optimize quality of life for all."

https://www.pipcpatients.org/news/pipc-response-to-trump-administrations-continued-push-for-mfn-pricing

10/08/2025

Listen in as Former Council of Economic Advisers acting chair Tomas Philipson details the growing costs of prescription medications and the trade fight with China:

Former Council of Economic Advisers acting chair Tomas Philipson discusses the costs of medicine prescriptions and the trade fight with China on 'The Bottom Line.'

10/06/2025

Exciting news: companies are investing in new U.S. facilities! This development accelerates access to and bolsters local economies.

More details at We Work For Health’s U.S. Biopharma Investment Watch:

We Work For Health brings together national and local business leaders, labor, biopharma, patient advocacy, and other healthcare-related stakeholders to support policies and initiatives that foster innovation and facilitate the delivery of lifesaving and life-enhancing medicines.

10/03/2025

"Despite decades of broken promises and trillions of dollars in spending, health care costs have skyrocketed while access to quality care has become more difficult for many American families."

slows innovations for : https://mostfavoredpatient.org/resources/mfp-letter

10/01/2025

The American innovation economy is thriving thanks in large part to , which fuel the investments that make new cures possible.

Learn more in the We Work For Health blog:

American innovation has long been the envy of the world, built on a foundation of strong intellectual property protections, public-private collaboration, and world-class research institutions. But today, that system is under threat. In Washington, misguided proposals like the Most Favored Nation (MF...

10/01/2025

"Unfortunately, the price controls that are driving firms out of Britain are now landing on American shores. Unless our own government changes course, we'll suffer the same fate as Britain."

won't work for the U.S.:

Unless our own government changes course, we'll suffer the same fate as Britain. Signs of drug companies losing patience with Britain's price controls have been apparent for years. The British government has ensured that drug firms have fewer resources for medicines.

09/29/2025

"This paradigm shift would mean the end of the Part D program. Having HHS bureaucrats impose foreign prices will lead to the restriction, elimination, or simply obsolescence of all the tools Part D plans use in price negotiations and designing formularies."

https://www.americanactionforum.org/insight/most-favored-nation-pricing-and-the-future-of-medicare-part-d/

09/26/2025

would be a cure worse than the disease. The administration would be wise to abandon this dangerous policy, and focus instead on reining in the shadowy middlemen and foreign free-riders at the root of America's high drug costs."

https://www.realclearhealth.com/articles/2025/09/19/most_favored_nation_drug_pricing_is_a_bad_deal_for_patients_1135971.html

09/24/2025

"If the cash price is cheaper than using insurance, as is often the case, patients have that option. Our polling showed that over 85% of likely voters support the White House’s direct-to-patient plan."

isn't the solution to accessible medications:

President Donald Trump's commonsense approach to healthcare reforms is already producing positive results for American families.